JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

A8604 GNF 5

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor
B1404 DCC-2036 (Rebastinib)

Target: FLT3|Bcr-Abl|Tie-2|KDR

Summary: Bcr-Abl inhibitor

≥27.7 mg/mL
A8232 Nilotinib(AMN-107)

1 Citation

Target: Bcr-Abl

Summary: Bcr-Abl kinase inhibitor,selective

≥26.5 mg/mL
A2149 Bosutinib (SKI-606)

1 Citation

Target: Bcr-Abl|Src

Summary: Potent Abl/Src kinases

≥26.5 mg/mL
A1805 Imatinib Mesylate (STI571)

Target: PDGFR|c-Kit|Bcr-Abl

Summary: Abl/c-kit/PDGFR inhibitor

≥29.5 mg/mL
A2133 Saracatinib (AZD0530)

3 Citation

Target: Src

Summary: Src/Abl inhibitor,potent and selective

≥27.1 mg/mL
A5467 Ponatinib (AP24534)

1 Citation

Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src

Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor

≥53.3 mg/mL
B5954 Dasatinib Monohydrate

Target: PDGFR|c-Kit|Bcr-Abl|Src

Summary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases.

≥25.3 mg/mL